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Abstract:  Novel metal-based compounds with therapeutic potential have 
become the subject of intense investigations in inorganic chemistry and bio-
medical science. Recently, strong dose-dependent cytotoxic activities of sele-
nosemicarbazone metal complexes against several human cancer cell lines 
were demonstrated. The aim of the present study was to investigate in vitro 
antioxidative potential of Ni(II), Cd(II) and Zn(II) selenosemicarbazone com-
plexes. All three investigated complexes exhibited high 2,2'-azinobis(3-ethyl-
benzothiazoline-6-sulphonic acid) radical cation (ABTS•+) scavenging capa-
city, comparable with ascorbic acid. In an acute toxicity study, administration 
of the compounds was performed orally to mice at single doses. The mice were 
observed for clinical signs, body weight effects and mortality for 14 days, after 
which they were sacrificed for gross organ necropsy. The body weight did not 
vary after administration, and the autoptic analysis failed to show appreciable 
macroscopic alterations of internal organs. Generally, the compounds exhibited 
low toxic effects as required for further in vivo therapeutic studies. 
Keywords: Ni(II), Cd(II) and Zn(II) complexes; selenosemicarbazones; antioxi-
dative activity; in vivo toxicity. 
INTRODUCTION 
Chalcogensemicarbazones are condensation derivates of chalcogensemicar-
bazides and carbonyl compounds. Interest in (thio)semicarbazone ligands has 
been driven, in part, by potentially beneficial biological activity of ligands and 
their metal complexes, including, antifungal, antimicrobial, anticancer, anti-
inflammatory and antiviral activities.1–4 However, total number of seleno-
semicarbazones and their metal complexes is much smaller in comparison to the 
corresponding O and S analogues, although results of few comparative studies 
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indicated that isosteric replacement of other chalcogen atoms with selenium 
resulted in a much more active compounds.5–11 The biological action of chalco-
gensemicarbazones is attributed to their chelating properties.1–4 
Our research group has been engaged in the systematic investigation of 
selenosemicarbazones derived from N-heteroaromatic aldehydes and ketones, in 
order to determine the driving force behind the coordination behaviour of this 
type of ligands, as well as to explore their biological activity. Similar to their 
sulphur analogues, selenosemicarbazones exhibit various binding modes with 
d-metals. Selenosemicarbazones of aliphatic and aromatic carbonyl compounds 
can act as mono- or bidentate ligands, but when N-heteroaromatic carbonyl com-
pound is used for synthesis of selenosemicarbazones, the coordination capacity 
can be extended by the presence of additional nitrogen atom suitable for chela-
tion. Accordingly, 2,6-diacetylpyridine bis(selenosemicarbazone) (H2dapsesc) is 
coordinated as pentadentate, via both selenium atoms, pyridine and both imine 
nitrogen atoms in Cd(II) and Zn(II) complexes (Scheme 1),12 while during the 
formation of the Ni(II) complex, elimination of hydrogen selenide from one side 
chain of the H2dapsesc ligand occurred.12 In the resulting Ni(II) complex, the 
modified ligand 2-{1-[6-(1-selenosemicarbazonoethyl)-2-pyridyl]ethylidene}-
hydrazine carbonitrile (H2hcn) is tetradentately coordinated (Scheme 1). 
 
Scheme 1. Structures of the investigated compounds. 
Over-production of activated oxygen species, generated by normal metabolic 
processes, is considered to be the main contributor of oxidative damage in bio-
molecules, thus inducing a broad spectrum of different diseases, in particular car-
diovascular, neurodegenerative disease and cancer.13 It is known that oxidative 
stress plays a multistep role in carcinogenesis, through a process of both cell 
mutation and proliferation. Although most cancer cells exhibit elevated oxidative 
stress with increased metabolic activity and the production of reactive oxygen 
species (ROS), the mechanism of action of many cancer chemotherapeutic drugs 
involves ROS-mediated apoptosis. For example, the classic anticancer agents 
cisplatin and adriamycin appear to produce ROS at excessive levels, resulting in 
DNA damage and cell death.14 Most thiosemicarbazone complexes contain redox   SELENOSEMICARBAZONE COMPLEXES AS POTENTIAL THERAPEUTICS  1505 
metal ions that potentially can activate O2 and generate OH·radicals. However, 
there are data that support but also data that exclude this activity as function of 
the nature of the ligand and the metal centre.4 The potential value of natural and 
synthetic antioxidants has already prompted scientists to search for cooperative 
effects of compounds which improve antioxidant activity and cytotoxicity.15 
Previous investigations showed that selenosemicarbazone complexes exhibited 
strong dose-dependent cytotoxic activity against a panel of several human tumour 
cell lines, and this effect was comparable to that of cisplatin.16–19 This study was 
undertaken with the aim to investigate the in vitro antioxidative potential of 
Ni(II), Cd(II) and Zn(II) selenosemicarbazone complexes. The analysis of the 
toxicity level of chemical compounds is one of the most important steps required 
for further biological studies.20 Bearing in mind the toxicity from high Se intake 
and that metal ions are generally toxic at high-dose levels, the second aim of the 
present study was to evaluate the acute oral toxicity of these novel metal-based 
compounds. 
EXPERIMENTAL 
Materials and methods 
2,6-Diacetylpyridine (dap, 99 %), was obtained from Acros Organics, while 
Ni(CH3COO)2·4H2O (purum p.a. ≥ 99.0 % KT), Zn(CH3COO)2·2H2O (purum p.a. ≥ 99.0 % 
KT) and Cd(CH3COO)2·2H2O (purum p.a. ≥ 99.0% KT) were obtained from Fluka. Dimethyl 
sulphoxide (DMSO dried, ≥ 99.5 %) was obtained from Merck (Darmstadt, Germany). 2,2'-
Azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS, anal. grade) and vitamin C 
(ascorbic acid, p.a) were purchased from Serva.  
Elemental analyses (C, H, N) were performed by standard micro-methods using an 
ElementarVario ELIII C.H.N.S=O analyzer. The IR spectra were recorded on a Perkin–Elmer 
FT-IR 1725X spectrometer in the region 4000–400 and 400–200 cm-1 as CsI tablets. Molar 
conductivities were measured at room temperature on a digital conductivity-meter Jenway- 
-4009. The NMR spectra (in DMSO-d6) were obtained using a Varian Gemini 2000 
instrument (1H at 200 MHz, 13C at 50.3 MHz). 
Synthesis of the tested compounds 
The ligand H2dapsesc was synthesized as described previously12 by the reaction of dap 
and selenosemicarbazide in the molar ratio 1:2. The complexes 1–3 (Scheme 1) were syn-
thesized by adding an aqueous solution of Zn(CH3COO)2·2H2O, Cd(CH3COO)2·2H2O or 
Ni(CH3COO)2·4H2O, respectively, into a suspension of H2dapsesc in EtOH.12 The Zn(II) and 
Cd(II) complexes were purified by vapour diffusion using DMSO as the inner solution and 
EtOH as the outer solvent. The purity of the synthesized compounds was tested by elemental 
analysis. The IR and NMR spectroscopy data, as well as the molar conductivity values were in 
good agreement with previously published data.12 
Analytic and spectral data for the ligand and 1–3 
H2dapsesc. Yield: 0.63 g (93 %); Anal. Calcd. for C11H15N7Se (FW: 403.20): C, 32.77; 
H, 3.75; N, 24.32 %. Found: C, 32.96; H, 3.70; N, 23.79 %. IR (KBr, cm-1): 3460 (s), 3375(s), 
3333 (s), 3249 (s), 3147 (s), 1591 (vs), 1491 (vs), 1440 (vs), 1397 (vs), 1260 (vs), 1086 (vs), 
786 (m). 1H-NMR (200 MHz, DMSO-d6, δ / ppm): 2.38 (3H, s, C7H3), 2.58 (3H, s, C10H3), 1506 DEKANSKI  et al. 
7.81 (1H, poorly resolved doublet, C4H), 8.01 (1H, poorly resolved triplet, C3H), 8.63 (1H, 
poorly resolved doublet, C2H), 8.65 and 8.75 (1H, s, N4HaHb), 8.97 (2H, s, N7H2), 10.85 
(1H, s, N3H), 14.16 (1H, s, Se2). 13C-NMR (50.3 MHz, DMSO-d6, δ / ppm): 12.6 (C7+C10), 
121.6 (C2+C4), 137.0 (C3), 149.9 (C6+C9), 153.7 (C1+C5), 175.5 (C8+C11). 
Complex 1. Yield: 0.10 g (86 %); Anal. Calcd. for C11H13N7Se2Zn (FW: 466.58): C, 
28.66; H, 3.52; N, 18.00 %. Found: C, 28.95; H, 3.51; N, 18.03 %. IR (KBr, cm-1): 3411 (m), 
3285 (m), 3157 (m), 1614 (m), 1482 (s), 1438 (vs), 1405 (s), 1285 (m), 1167 (m), 1024 (m), 
714 (w). 1H-NMR (200 MHz, DMSO-d6, δ / ppm): 2.46 (6H, s, C7H3+C10H3), 6.82 (4H, s, 
N4H2+N7H2), 7.61 (2H, poorly resolved doublet, C2H+C4H), 7.92 (1H, poorly resolved 
triplet, C3H). 13C-NMR (50.3 MHz, DMSO-d6, δ / ppm): 17.4 (C7+C10), 124.1 (C2+C4), 
138.9 (C3), 153.6 (C6+C9), 155.8 (C1+C5), 173.0 (C8+C11). Conductivity (ΛM / Ω-1cm2 
mol-1 (1×10-3 mol dm-3 in DMF)): 0.73. 
Complex 2. Yield 0.07 g (55 %); Anal. Calcd. for C11H13N7Se2Cd (FW: 513.60): C, 
25.72; H, 2.55; N, 19.09 %. Found: C, 25.66; H, 2.54; N, 18.53 %. IR (KBr, cm-1): 3476 (m), 
3285 (m), 3162 (w), 1607 (m), 1495 (s), 1435 (m), 1407 (s), 1170 (m), 1019 (w), 702 (w). 1H- 
-NMR (200 MHz, DMSO-d6,  δ / ppm): 2.42 (6H, s, C7H3+ C10H3), 6.93 (4H, s, 
N4H2+N7H2), 7.80 (2H, d, 3J = 7.9 Hz, C2H+C4H), 8.12 (1H, t, 3J = 7.9 Hz, C3H). 13C-NMR 
(50.3 MHz, DMSO-d6, δ / ppm): 14.6 (C7+C10), 121.9 (C2+C4), 140.9 (C3), 145.4 (C6+C9), 
150.5 (C1+C5), 174.6 (C8+C11). Conductivity (ΛM / Ω-1cm2 mol-1 (1×10-3 mol dm-3 in 
DMF)): 1.17.  
Complex  3. Yield 0.26 g (84 %); Anal. Calcd. for C11H11N7SeNi (FW: 378.91): C, 
34.87; H, 2.93; N, 25.88 %. Found: C, 34.64; H, 2.86; N, 25.47 %. IR (KBr, cm-1): 3430 (m), 
3315 (m), 3153 (s), 2176 (vs), 1648 (s), 1595 (w), 1535 (s), 1498 (s), 1444 (m), 1407 (m), 
1370 (m), 1329 (m), 1289 (m), 1223 (w), 1172 (m), 1107 (m), 1076 (m), 1045 (m), 797 (m), 
766 (w), 712 (m). 1H-NMR (200 MHz, DMSO-d6, δ / ppm): 2.34 (3H, s, C10H3), 2.51 (3H, s, 
C7H3), 7.87 (2H, s, N4H2), 7.98 (1H, poorly resolved doublet, C2H), 8.18 (1H, poorly 
resolved doublet, C4H), 8.41 (1H, poorly resolved triplet, C3H). Conductivity (ΛM / Ω-1cm2 
mol-1 (1×10-3 mol dm-3 in DMF)): 1.35. 
Free radical scavenging assay 
The total antioxidant activity assay using ABTS cation radicals was performed according 
to the previously published procedure21 with some modifications. Briefly, ABTS was dis-
solved in water to a concentration of 7 mM and its cation radicals were produced in a reaction 
with 2.45 mM potassium persulphate. The resulting mixture was kept in the dark at room 
temperature for 12–16 h before use. Prior to the assay, the solution was diluted with miliQ 
water (about 1:79, v/v) to give an absorbance of 0.70±0.02 at 734 nm. After the addition of 2 
mL of diluted ABTS cation radical solution to 0.2 mL of a fixed concentration of the com-
pounds, the absorbance at 734 nm was recorded exactly 30 min after the initial mixing. 
Results are presented as mean ± standard deviation. A minimum of three independent 
experiments were performed. The log sigmoid dose–response curves of free radical scaveng-
ing activity of tested compounds were generated using the Origin 7.0 software package (Mic-
rocal Software Inc., Northampton, MA, USA). The IC50 values were determined by post hoc 
regression analysis of the linear segments of the sigmoid dose response curves. Calibration 
curves of the standards and samples were considered as linear if R2 > 0.98. 
Animals 
This study was run in accordance to the statements of European Union regarding hand-
ling of experimental animals (86/609/EEC), and approved by the Ethical Committee for Labo-  SELENOSEMICARBAZONE COMPLEXES AS POTENTIAL THERAPEUTICS  1507 
ratory Animals, Galenika a.d., Belgrade (permit No 02/20.01.2012.). Adult, female (nulli-
parous and non-pregnant) NMRI/Han mice were provided by Biomedical Research Centre, 
R&D Institute, Galenika a.d. (Belgrade, Serbia). Before experiment, the mice were housed 5 
per cage under constant environmental conditions (20–24 °C; 12 h light/dark cycle), and had 
access to standard pelleted food and water ad libitum.  
Acute oral toxicity study 
Acute oral toxicity test was run strictly in accordance with OECD Guidelines for the 
Testing of Chemicals, Section 4: Health Effects: Test No. 423: Acute Oral toxicity – Acute 
Toxic Class Method.22 The principle of the test is that, based on a stepwise procedure with the 
use of a minimum number of animals per step, sufficient information is obtained on the acute 
toxicity of a test substance. The substances were tested using a stepwise procedure. In each 
step, three female mice were used since they are generally slightly more sensitive. The 
absence or presence of compound-related mortality of the animals dosed at one step deter-
mined the next step, i.e., no further testing is needed, dosing of three additional animals with 
the same dose, or dosing of three additional animals at the next higher or the next lower dose. 
The animals, which were 8–10 weeks old and weighed 22–30 g, were fasted for 4 h before the 
experiment and divided into experimental and control groups. Test samples were dissolved 
first in DMSO, and distilled water was added to obtain the final concentration of the tested 
compounds (the final concentration of DMSO was 20 %). The control group was treated with 
20 % DMSO. A single dose of 300 and 2000 mg kg-1 b.wt. of Ni (II), Cd(II) and Zn(II) 
complexes was administered intragastrically (i.g.) using a metal tube for gavage. Fixed 
volume of 0.5 mL was administrated per mouse. Food was returned to the animals 3 h after 
dosing. Individual weights were determined at the start of the fasting time (day 0), imme-
diately before the test substance was administered (day 0) and on the test days 1, 2, 4, 7, and 
14. The animals were observed for clinical signs of toxicity while handled before and after 
fasting, during the first 30 min after dosing, at least two more times within 4–4.5 h after 
dosing, and daily thereafter. Observations for abnormal behavioural signs, somnolence, dizzi-
ness, restlessness, neurological signs, respiratory distress or mortality were conducted twice 
daily. At the end of the test (day 14), the mice were sacrificed by cervical dislocation, and 
gross pathological changes in the main organs (brain, liver, kidney, spleen, gastric and intes-
tinal mucosa) were evaluated.  
RESULTS AND DISCUSSION 
The biological activities of semicarbazones and thiosemicarbazones were 
reported to increase upon coordination with the metal ions. The metal complex 
could be more active than the free ligand, and could exhibit biological activities 
that are not shown by the free ligand. In addition, some adverse effects may 
decrease upon complexation. Moreover, coordination may lead to significant 
reduction of drug-resistance. Therefore, studies on novel metal-based compounds 
with therapeutic potential have become an area of intense investigation in biome-
dicine and inorganic chemistry.23,24 In the present study, the antioxidative poten-
tial and acute toxicity level of three synthesised selenosemicarbazone metal com-
plexes 1–3 (Scheme 1) were investigated.  
There are various antioxidant activity assays, each having their specific tar-
get within the matrix and all of them with advantages and disadvantages. The 1508 DEKANSKI  et al. 
ABTS assay used in this study represents one of the most important and widely 
used assays.25 This colorimetric test provides determination of the antioxidant 
capacity of natural and synthetic compounds since the ABTS radical decolorizes 
in the presence of antioxidants. The free radical scavenging capacity (FRSC in 
%) of the ligand H2dapsesc, the complexes 1–3 and metal salts used in synthesis, 
as well as the ascorbic acid as positive control and DMSO as the vehicle control 
is expressed as 50 % inhibitory concentration (IC50 in μM, Table I), defined as 
the concentration of the tested compound leading to a 50 % reduction of the free 
radical concentration. The IC50 values for the tested compounds were calculated 
from log sigmoidal dose response inhibition curves by post hoc linear regression 
analysis. These results clearly indicated that the complexes 1–3  exhibited an 
excellent ABTS radical cation-scavenging effect, comparable to that of a refe-
rence antioxidant, Vitamin C. The antioxidative capacity of the ligand was lower 
by an order of magnitude compared to the activity of the complexes. It is to be 
noted that no significant radical scavenging activities were observed in the expe-
riment carried out under the same experimental conditions with the metal salts 
used in the syntheses of the complexes, even up to the concentration of 1.0 mM. 
The IC50 values (Table I) indicated that the ligand and the complexes showed 
antioxidant activity in the following order: 2 > 1 > 3 > H2dapsesc. It can be 
assumed that coordination of the ligand in anionic form promotes the ligand-cen-
tered reduction of the CH3C=N double bond in the complexes, which is reflected 
in the higher antioxidative potential of the complexes compared to the free ligand, 
as was registered for related Ga(III) complexes with thiosemicarbazones.26 
TABLE I. IC50 values (in μM) calculated from ABTS radical cation scavenging assay of the 
tested compounds and the standard (vitamin C) 
Compound  IC50 / μM 
H2dapsesc 557±54 
[Zn(dapsesc)] (1) 29.51±1.50 
[Cd(dapsesc)] (2) 21.62±0.83 
[Ni(hcn)] (3) 35.59±5.30 
Zn(CH3COO)2·2H2O >  1000 
Cd(CH3COO)2·2H2O >  1000 
Ni(CH3COO)2·4H2O >  1000 
Vitamin C  21.35±2.75 
It is known that selenium represents one of the most important micro-nu-
trients in human diet regarding antioxidant activity. It does not act directly on 
free radicals but is an indispensable part of most antioxidant enzymes (metallo-
enzymes, glutathione peroxidase) that would have no effect without it.27 The 
mode of anticancer action of Se is not fully understood but several mechanisms 
including antioxidant protection by selenoenzymes have been proposed.28 Fur-
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formation. It plays a role as an inhibitor of NADPH oxidases, which catalyze the 
production of the superoxide radical anion from oxygen by using NADPH as an 
electron donor. Zinc is present in superoxide dismutase, an important antioxidant 
enzyme that converts the superoxide radical anion into hydrogen peroxide. 
Finally, zinc induces the production of metallothionein that is a scavenger of the 
hydroxyl radical, and also competes with copper for binding to the cell wall, thus 
decreasing the production of hydroxyl radicals.29 Taken together, the present 
preliminary  in vitro results and these known properties of selenium and zinc 
allow the proposal that these metal complexes are worthy of further investigation 
under in vivo conditions. 
However, the toxicity and carcinogenicity of metal ions should not be 
neglected. The primary route for their toxicity is depletion of glutathione and 
bonding to sulfydryl groups of proteins.30 In addition, the unregulated intake of 
dietary or pharmacological selenium, mainly in the form of the inorganic Se 
compound, sodium selenite, could potentially expose the body tissues to toxic 
levels of Se with the subsequent negative consequences on DNA integrity. Due 
to a broad interest for the beneficial effects of Se on human health and cancer 
prevention and therapy, studies investigating the negative effects such as toxicity 
from high Se intake are also highly required.28 Therefore, a toxicological study 
of the investigated selenosemicarbazone metal complexes was conducted as one 
of the most important steps required for further studies of biological activity. The 
acute toxicity evaluation was based on an established protocol, internationally 
recognized as a reference standard tool for chemical tests. The OECD 420 guide-
line – Fixed-Dose Procedure for Assessing Oral Acute Toxicity22 was followed. 
Acute oral toxicity refers to those adverse effects occurring following oral admi-
nistration of a single dose of a substance. According to globally harmonized 
system of classification and labelling of chemicals (GSH),31 substances are 
assigned to one of the five toxicity categories based on LD50 (oral and dermal) or 
LC50 (inhalation). For the evaluation of acute oral toxicity, a single dose (300 and 
2000 mg kg–1) was orally administered to female mice. The doses used were 
based on the previous toxicological data on the structurally related substance, 
N-{4-[(E)-((aminothioxomethylhydrazono)methyl]phenyl}acetamide (thioaceta-
zone), which was helpful in the selection of the most appropriate initial dose. 
Namely, the median lethal dose (LD50) for thioacetazone was determined as 950 
mg kg–1 after oral administration in mouse.31 Thus a starting dose 300 mg kg–1 
was employed in the present study. The results are presented in Table II. 
At the dose level of 300 mg kg–1 body weight, no mortality was observed, 
but some signs and unusual symptoms during the first 4 h of the acute toxicity 
protocol were observed, such as exciting behavioural (agitation, touch response), 
inhibitory (sleepiness) and other characteristics (piloerection). It was observed 
that the compounds did not cause any gross behavioural alterations, such as 1510 DEKANSKI  et al. 
convulsion, dizziness or respiratory distress. No clinical signs of toxicity were 
observed in the group that received [Ni(hcn)] in the lower dose. After that, the 
toxicity level of the Ni(II), Cd(II) and Zn(II) selenosemicarbazone complexes 
were evaluated at the maximum dose of 2000 mg kg–1 administered orally to the 
4 h-fasted mice. At the higher dose, toxic symptoms, such mild agitation, touch 
response in one animal and sleepiness in the [Cd(dapsesc)] group, ataxia and 
somnolence with a fatal effect in [Ni(hcn)] group, were observed. During the 
study period of two weeks, no death occurred in the animals treated with the 
Cd(II) and Zn(II) selenosemicarbazone complexes, which indicates that the lethal 
dose of the compounds is above 2000 mg kg–1 body weight in mice and that the 
compounds could be considered to be less harmful at this dose. No test sub-
stance-related effects on body weight occurred. The mean body weights of the 
test mice were similar to those of the control group throughout the study (data not 
shown). Sporadic body weight losses of up to 5 % were not considered test sub-
stance-related, because the decreases were only over a one- or two-day period 
and did not occur the day after dosing. No gross lesions were present in the mice 
at necropsy. In addition, macroscopic examination revealed that the organs taken 
presented aspects of colour, size and texture, showing no difference from the 
control group. 
TABLE II. Parameters of acute toxicity observed in adult female mice, treated with different 
oral doses of Ni(II), Cd(II) and Zn(II) selenosemicarbazone complexes; –, no effect; +, mild 
effect; ++, moderate effect; +++, major effect 
Clinical sign 
Compound/Dose, mg kg-1 
Control  
(20 % DMSO)  [Ni(hcn)] [Cd(dapsesc)]  [Zn(dapsesc)] 
300  2000  300  2000  300  2000 
Agitation  –  –  –  +  +  –  – 
Convulsion  –  –  –  –  –  –  – 
Ataxia  –  +++  +  –  –  –  – 
Touch response  –  –  +  +  –  –  – 
Piloerection  –  –  –  –  +  –  – 
Sleepiness  –  –  –  +  +  –  + 
Somnolence  –  +++  –  –  –  ++  – 
Respiratory distress  –  –  –  –  –  –  – 
Mortality  0/6  6/6  0/6  0/6  0/6  0/6  0/6 
The absence of mortality at concentrations as high as 2000 mg kg–1 b.wt. of 
the Cd(II) and Zn(II) complexes did not allow the calculation of the median 
lethal dose (LD50) value. Hence, the Cd(II) and Zn(II) complexes investigated in 
this study belong to the so-called category 5 or unclassified according to GSH 
classification.31 Therefore, these compounds show low acute toxicological risk. 
The absence of gross behavioural alteration is also another indication of lack of 
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therapeutic index or therapeutic ratio could be expected. A higher therapeutic 
index is preferable to a lower one, and means that much higher doses of these 
compounds are required to reach the lethal/toxic threshold than the dose which 
will lead to a therapeutic effect.  
CONCLUSIONS 
The investigated compounds showed high in vitro antioxidative potential. 
Accordingly, they are good candidates for the prevention or treatment of a broad 
range of pathological conditions mediated by uncontrolled oxidative processes. 
They also exhibited low toxic effects as required for further in vivo therapeutic 
studies. The obtained results invoke further preclinical studies that should show 
their efficacy in different oxidative stress related disorders. In addition, long-term 
toxicological studies with repeated doses are necessary for the final safety evalu-
ation. 
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ИЗВОД 
ВИСОКИ АНТИОКСИДАТИВНИ ПОТЕНЦИЈАЛ И МАЛИ ТОКСИЧНИ ЕФЕКАТ 
СЕЛЕНОСЕМИКАРБАЗОНСКИХ КОМПЛЕКСА 
ДРАГАНА ДЕКАНСКИ
1, ТАМАРА ТОДОРОВИЋ
2, ДРАГАНА МИТИЋ
2, НЕНАД ФИЛИПОВИЋ
3, НАТАЛИЈА 
ПОЛОВИЋ
2 И КАТАРИНА АНЂЕЛКОВИЋ
2 
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11000 Београд, 
2Хемијски факултет, Универзитет у Београду, Студентски трг 12–16, 11000 Београд 
и 
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Нова једињења на бази метала са терапеутским дејством постала су предмет истра-
живања у неорганској хемији и биомедицинским наукама. Показана је јака дозно-за-
висна цитотоксична активност комплекса селеносемикарбазона на већем броју ћелиј-
ских линија хуманих ћелија канцера. Циљ рада је испитивање in vitro антиоксидативног 
дејства селеносемикарбазонских комплекса никла, цинка и кадмијума. Сва три испити-
вана комплекса показала су јаку антиоксидативну активност према ABTS радикалу, упо-
редиву са активношћу аскорбинске киселине. Током испитивања акутне токсичности, 
једињења су орално давана мишевима у појединачним дозама и праћени су клинички 
знаци, тежина тела и морталитет након 14 дана, а потом су животиње жртвоване ради 
аутопсије органа. Тежина тела није варирала након апликације. Генерално, једињења су 
показала мали токсични ефекат што и захтева будуће in vivo терапеутско испитивање. 
(Примљено 15. марта, ревидирано 27. марта 2013) 
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